HC Wainwright Has Bearish Forecast for GLSI FY2026 Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Free Report) – Research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Greenwich LifeSciences in a note issued to investors on Wednesday, November 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($1.46) per share for the year, down from their previous estimate of ($1.29). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.36) EPS and FY2027 earnings at ($1.46) EPS.

Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06).

Other research analysts also recently issued reports about the stock. Wall Street Zen raised shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings upgraded shares of Greenwich LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Greenwich LifeSciences currently has an average rating of “Hold” and an average price target of $70.00.

Read Our Latest Analysis on Greenwich LifeSciences

Greenwich LifeSciences Trading Down 1.6%

Shares of NASDAQ:GLSI opened at $19.48 on Friday. The company has a 50 day moving average of $16.87 and a 200 day moving average of $20.77. The stock has a market cap of $285.95 million, a P/E ratio of 0.00 and a beta of 1.57. Greenwich LifeSciences has a 12 month low of $7.78 and a 12 month high of $34.10.

Hedge Funds Weigh In On Greenwich LifeSciences

Institutional investors have recently added to or reduced their stakes in the company. Ancora Advisors LLC boosted its position in shares of Greenwich LifeSciences by 101.2% in the 3rd quarter. Ancora Advisors LLC now owns 21,610 shares of the company’s stock worth $390,000 after purchasing an additional 10,870 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Greenwich LifeSciences by 44.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company’s stock valued at $1,025,000 after buying an additional 17,464 shares in the last quarter. BlackRock Inc. bought a new position in Greenwich LifeSciences during the 2nd quarter valued at approximately $11,398,000. Deutsche Bank AG purchased a new position in Greenwich LifeSciences during the second quarter valued at $126,000. Finally, Bank of New York Mellon Corp purchased a new stake in Greenwich LifeSciences during the 2nd quarter valued at about $1,124,000. Institutional investors own 4.16% of the company’s stock.

Trending Headlines about Greenwich LifeSciences

These are some of the GLSI headlines that stood out recently:

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.

Read More

Earnings History and Estimates for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.